- Trials with a EudraCT protocol (919)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
919 result(s) found for: All cause mortality.
Displaying page 1 of 46.
EudraCT Number: 2022-003218-36 | Sponsor Protocol Number: 82646 | Start Date*: 2023-06-05 |
Sponsor Name:Radboudumc | ||
Full Title: The safety of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction and the effect on intramyocardial haemorrhage | ||
Medical condition: Acute myocardial infarction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003510-16 | Sponsor Protocol Number: EFC15156 | Start Date*: 2018-05-07 | ||||||||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabet... | ||||||||||||||||||
Medical condition: Cardiovascular diseases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) NL (Completed) ES (Prematurely Ended) LV (Completed) LT (Completed) GB (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Completed) CZ (Prematurely Ended) DE (Completed) SK (Completed) HU (Completed) FI (Completed) PT (Completed) GR (Completed) PL (Completed) IE (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005446-15 | Sponsor Protocol Number: 202100617 | Start Date*: 2022-06-30 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease | ||
Medical condition: Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020793-42 | Sponsor Protocol Number: 170782 | Start Date*: 2010-10-26 |
Sponsor Name:Clinic for Thoracic and Cardiovascular Surgery, Heart Centre North Rhine-Westfalia | ||
Full Title: The effect of vitamin D on all-cause mortality in congestive heart failure patients | ||
Medical condition: Substitution of low vitamin D levels in congestive heart failure patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001099-21 | Sponsor Protocol Number: 2010-04-23 | Start Date*: 2011-05-19 |
Sponsor Name:Population Health Research Institute | ||
Full Title: SIRS Steroids In caRdiac Surgery Trial | ||
Medical condition: From available evidence, corticosteroids attenuate the inflammatory response to CPB which is felt to contribute to morbidity and mortality in cardiac surgery patients. The meta-analysis of the lite... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003153-28 | Sponsor Protocol Number: ALN-TTRSC02-003 | Start Date*: 2019-12-23 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: HELIOS-B: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Outcomes, Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with C... | |||||||||||||
Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) PT (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) SI (Completed) NO (Trial now transitioned) IE (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) NL (Trial now transitioned) HR (Trial now transitioned) CZ (Trial now transitioned) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000441-32 | Sponsor Protocol Number: REDOX2016 | Start Date*: 2016-10-27 |
Sponsor Name:Blekinge county council | ||
Full Title: REgistry-based randomized controlled trial of treatment Duration and mortality in long-term OXygen therapy (REDOX) A Multicenter, Phase III, Registry-Based, Randomized Controlled Trial (R-RCT) | ||
Medical condition: Chronic respiratory failure requiring LTOT (long-term oxygen treatment) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005911-27 | Sponsor Protocol Number: S64445 | Start Date*: 2021-03-17 |
Sponsor Name:KU Leuven | ||
Full Title: The DAWN antivirals trial: the efficacy of antivirals for COVID-19 infections presenting to ambulatory care: a randomized controlled trial. | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-005698-21 | Sponsor Protocol Number: EFC11570 | Start Date*: 2013-03-05 | |||||||||||
Sponsor Name:sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recentl... | |||||||||||||
Medical condition: Acute coronary syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) BE (Completed) NO (Completed) EE (Completed) LT (Completed) HU (Completed) ES (Completed) CZ (Completed) LV (Completed) DE (Completed) IT (Completed) BG (Completed) FI (Completed) AT (Completed) PT (Completed) DK (Completed) NL (Completed) PL (Completed) SK (Completed) SI (Completed) HR (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000486-37 | Sponsor Protocol Number: CHF201701 | Start Date*: 2019-03-27 |
Sponsor Name:Heart Initiative | ||
Full Title: STRONG-HF: Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP testing, of Heart Failure therapies | ||
Medical condition: Acute Heart Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) HR (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002505-10 | Sponsor Protocol Number: NL77754.018.21 | Start Date*: 2021-11-30 | |||||||||||||||||||||
Sponsor Name:Amsterdam University Medical Centre | |||||||||||||||||||||||
Full Title: Rescue Alkaline Phosphatase In Defense against all cause Acute Kidney Injury (RAPID-AKI) | |||||||||||||||||||||||
Medical condition: Acute kidney injury | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002504-39 | Sponsor Protocol Number: HERO-19 | Start Date*: 2020-11-10 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Hamburg Edoxaban foR anticoagulation in COvid-19 study | |||||||||||||
Medical condition: COVID-19 [Coronavirus disease 2019] | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001225-16 | Sponsor Protocol Number: 3001077 | Start Date*: 2004-10-28 |
Sponsor Name:Orion Pharma | ||
Full Title: Survival of patients with acute heart failure in need of intravenous inotropic support; a multicentre parallel- group, randomised, double- blind, double- dummy study of levosimendan versus dobutami... | ||
Medical condition: Acutely decompensated heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023093-39 | Sponsor Protocol Number: SIRS | Start Date*: 2011-09-08 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE | |||||||||||||
Full Title: Steroids In caRdiac Surgery Trial | |||||||||||||
Medical condition: Require CPB for any cardiac surgical procedure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) CZ (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002306-39 | Sponsor Protocol Number: 156-03-236 | Start Date*: 2005-07-15 |
Sponsor Name:Otsuka Maryland Research Institute, Inc. | ||
Full Title: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure | ||
Medical condition: Subjects hospitalized with worsening congestive heart failure (CHF). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001582-16 | Sponsor Protocol Number: RF-2016-02361583 | Start Date*: 2018-08-09 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: Efficacy of Albumin Replacement and Balanced Crystalloid Solutions in Septic Shock (the ALBIOSS-BALANCED trial): a 2-by-2 factorial, investigator-initiated, open-label, multicenter, randomized, con... | |||||||||||||
Medical condition: Septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001250-21 | Sponsor Protocol Number: 2020/3078 | Start Date*: 2020-04-03 |
Sponsor Name:GUSTAVE ROUSSY | ||
Full Title: COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients | ||
Medical condition: Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005439-15 | Sponsor Protocol Number: CAP | Start Date*: Information not available in EudraCT |
Sponsor Name:Akershus University Hospital | ||
Full Title: Apixaban for treatment of venous thrombosis in patients with cancer. | ||
Medical condition: Venous thrombosis in patients with cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001767-86 | Sponsor Protocol Number: COVIRL-002 | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive... | |||||||||||||
Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003938-14 | Sponsor Protocol Number: MK-5592-069(P06200) | Start Date*: 2013-04-09 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069) | |||||||||||||
Medical condition: Invasive aspergillosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) BE (Completed) LT (Prematurely Ended) PT (Completed) GB (Completed) EE (Completed) IT (Completed) PL (Completed) GR (Completed) FR (Completed) HU (Completed) CZ (Completed) HR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
